title: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).
abstract: BACKGROUND
  The aim of this study was to evaluate the efficacy of adjuvant chemotherapy after resection for gastric cancer in a randomized controlled trial.
  
  
  METHODS
  After curative resection, stage II-III-IVM0 gastric cancer patients were randomly assigned to postoperative chemotherapy or surgery alone. 5-Fluorouracil (5-FU) 800 mg/m(2) daily (5-day continuous infusion) was initiated before day 14 after resection. One month later, four 5-day cycles of 5-FU (1 g/m(2) per day) plus cisplatin (100 mg/m(2) on day 2) were administered every 4 weeks.
  
  
  RESULTS
  The study was closed prematurely after enrollment of 260 patients (79.7% N+), owing to poor accrual. At 97.8 months median follow-up, 5- and 7-year overall survival were 41.9% and 34.9% in the control group versus 46.6% and 44.6% in the chemotherapy group (P=0.22). Cox model hazard ratios were 0.74 [95% confidence interval (CI) 0.54-1.02; P=0.063] for death and 0.70 (95% CI 0.51-0.97; P=0.032) for recurrence. An invaded/removed lymph nodes ratio >0.3 was the main independent poor prognostic factor identified by multivariate analysis (P=0.0001). Because of toxicity, only 48.8% of patients received more than 80% of the planned dose.
  
  
  CONCLUSIONS
  There was no statistically significant survival benefit with this toxic cisplatin-based adjuvant chemotherapy, but a risk reduction in recurrence was observed.
authors.affiliation: University Hospital, Reims, France. obouche@chu-reims.fr
authors.forename: O
authors.initials: O
authors.lastname: Bouché
authors.forename: M
authors.initials: M
authors.lastname: Ychou
authors.forename: P
authors.initials: P
authors.lastname: Burtin
authors.forename: L
authors.initials: L
authors.lastname: Bedenne
authors.forename: M
authors.initials: M
authors.lastname: Ducreux
authors.forename: G
authors.initials: G
authors.lastname: Lebreton
authors.forename: J
authors.initials: J
authors.lastname: Baulieux
authors.forename: B
authors.initials: B
authors.lastname: Nordlinger
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: J F
authors.initials: JF
authors.lastname: Seitz
authors.forename: J M
authors.initials: JM
authors.lastname: Tigaud
authors.forename: E
authors.initials: E
authors.lastname: Echinard
authors.forename: N
authors.initials: N
authors.lastname: Stremsdoerfer
authors.forename: C
authors.initials: C
authors.lastname: Milan
authors.forename: P
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016019:Survival Analysis
chemical_list: D002945:Cisplatin; D005472:Fluorouracil